Linezolid Antimicrobial Coverage

Primary Gram-Positive Coverage

The Infectious Diseases Society of America recommends linezolid as first-line therapy for MRSA skin and soft-tissue infections (Grade 1A recommendation) and as an alternative to vancomycin for nosocomial pneumonia caused by MRSA 1, 2
Linezolid demonstrates excellent activity against Methicillin-resistant Staphylococcus aureus (MRSA), including both nosocomial and community-acquired strains 1
Linezolid maintains in vitro activity against Vancomycin-intermediate S. aureus (VISA) and Vancomycin-resistant S. aureus (VRSA) 2
Linezolid covers all strains of Streptococcus pneumoniae, including multidrug-resistant isolates (MDRSP) resistant to penicillin, second-generation cephalosporins, macrolides, tetracycline, and trimethoprim/sulfamethoxazole 3

Linezolid lacks clinically useful activity against aerobic Gram-negative organisms, including Pseudomonas aeruginosa, Enterobacteriaceae, and Haemophilus influenzae, as well as atypical pathogens such as Mycoplasma pneumoniae, Chlamydia pneumoniae, or Legionella species 2, 3

Linezolid achieves excellent tissue penetration, including into biofilms and poorly vascularized tissues such as the prostate 2
The oral formulation of linezolid has 100% bioavailability, allowing seamless IV-to-oral transition when patients can tolerate oral medications 1

Vancomycin-resistant Enterococcus faecium (VRE) is susceptible to linezolid, according to the Clinical Microbiology and Infection guideline 4

The Infectious Diseases Society of America recommends linezolid for necrotizing fasciitis (in combination with broad-spectrum agents), as stated in the Clinical Microbiology and Infection guideline 4
The World Journal of Emergency Surgery reports that linezolid has 100% oral bioavailability, allowing seamless IV-to-oral transition when patients can tolerate oral medications, which enables shorter hospital stays and earlier discharge compared to vancomycin 5